Quick Takeaways
- CATX - Perspective Therapeutics, Inc. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: +$42,241.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 17 Insiders of Perspective Therapeutics, Inc.
- Symbol
- CATX on NYSE
- Location
- Seattle, WA
What Changed
- Buy value: $42,241; sell value: $0.
- Net share flow: +20,498.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$42,241.
Buys
$42,241
Shares: 20,498
Insiders: 2
Sells
$0
Shares: 0
Insiders: 0
Net
+$42,241
Shares: +20,498
Insiders: 2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 20,498 | 0 | $42,241 | $0 | +$42,241 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Perspective Therapeutics, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10%+ Owner | $110,934,724 | Filing P/S | 06 Mar 2024 | ||
| Lori A. Woods | Director | $400,989 | Mixed | 02 Mar 2026 | ||
| Robert F. Williamson III | Director | $394,522 | +$19,946 | +5.3% | Mixed | 02 Mar 2026 |
| Johan M. Spoor | Chief Executive Officer, Director | $194,133 | Mixed | 02 Mar 2026 | ||
| Jonathan Robert Hunt | Chief Accounting Officer | $121,202 | +$22,295 | +23% | Filing P/S | 02 Mar 2026 |
| Juan Graham | Chief Financial Officer | $79,490 | Filing P/S | 28 Mar 2025 | ||
| Mark John Austin | VP Finance/Prin Fin&Acct Offic | $30,251 | Mixed | 17 Jul 2024 | ||
| Philip J. Vitale | Director | Mixed | 21 Jul 2022 | |||
| Alan Hoffmann | Director | Mixed | 21 Jul 2022 | |||
| William Cavanagh | Chief R&D Officer | Mixed | 21 Jul 2022 | |||
| Frank Morich | Director | Mixed | 02 Mar 2026 | |||
| Michael W. McCormick | Director | Mixed | 21 Feb 2023 | |||
| Jennifer Streeter | COO & VP of HR | Mixed | 12 Jun 2023 | |||
| Markus Puhlmann | Chief Medical Officer | Mixed | 02 Mar 2026 | |||
| Maria E. Martinez | Director | Mixed | 02 Mar 2026 | |||
| Joel Sendek | Chief Financial Officer | Mixed | 04 Sep 2025 | |||
| Heidi Henson | Director | Mixed | 02 Mar 2026 |
Top shareholders of Perspective Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
116,773,394
|
$110,934,724 | — | 06 Mar 2024 | |
| Commodore Capital LP |
13D/G
|
— |
9.9%
|
11,939,753
|
$29,968,780 | $0 | 02 Feb 2026 | |
| Avidity Partners Management LP |
13D/G
13F
|
Company |
5.3%
|
6,049,999
|
$29,523,995 | +$15,659,798 | 20 Feb 2026 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
4.6%
|
5,251,363
|
$21,898,184 | $0 | 31 Mar 2026 | |
| TCG Crossover GP II, LLC |
13D/G
|
Chen Yu |
6.9%
|
7,915,567
|
$21,767,809 | $0 | 03 Feb 2026 | |
| Qatar Investment Authority |
13D/G
|
— |
6.2%
|
7,073,308
|
$19,451,597 | $0 | 04 Feb 2026 | |
| MORGAN STANLEY |
13F
13D/G
|
Company |
6%
from 13D/G
|
4,474,522
|
$12,304,936 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.1%
|
3,490,658
|
$9,599,310 | — | 31 Dec 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
1%
|
1,184,500
|
$4,989,875 | — | 31 Dec 2025 | |
| Nicholson Wealth Management Group, LLC |
13F
|
Company |
1.4%
|
1,617,993
|
$4,449,481 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
1,414,522
|
$3,890,676 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.2%
|
1,406,374
|
$3,867,528 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
1.1%
|
1,274,007
|
$3,503,519 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1%
|
1,198,644
|
$3,296,271 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1%
|
1,141,247
|
$3,138,429 | — | 31 Dec 2025 | |
| Patient Square Capital LP |
13F
|
Company |
0.99%
|
1,132,815
|
$3,115,241 | — | 31 Dec 2025 | |
| Hills Bank & Trust Co |
13F
|
Company |
0.82%
|
938,200
|
$2,580,050 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.81%
|
926,331
|
$2,547,410 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.58%
|
663,830
|
$1,825,533 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.47%
|
535,477
|
$1,472,562 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.38%
|
439,214
|
$1,207,839 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.37%
|
424,519
|
$1,167,427 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.36%
|
406,732
|
$1,118,514 | — | 31 Dec 2025 | |
| WealthPlan Investment Management, LLC |
13F
|
Company |
0.35%
|
404,071
|
$1,111,195 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.31%
|
352,493
|
$969,356 | — | 31 Dec 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.31%
|
349,973
|
$962,426 | — | 31 Dec 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.29%
|
328,667
|
$903,834 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.28%
|
314,180
|
$863,995 | — | 31 Dec 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
0.4%
from 13D/G
|
307,055
|
$844,401 | — | 31 Dec 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.26%
|
300,000
|
$825,000 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.24%
|
270,491
|
$743,850 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.23%
|
263,995
|
$725,986 | — | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.19%
|
213,759
|
$587,837 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.17%
|
188,605
|
$518,662 | — | 31 Dec 2025 | |
| Rothschild Wealth LLC |
13F
|
Company |
0.14%
|
164,714
|
$452,964 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.14%
|
159,837
|
$439,552 | — | 31 Dec 2025 | |
| Lori A. Woods |
3/4/5
|
Director |
—
mixed-class rows
|
238,267
mixed-class rows
|
$400,989 | — | 02 Mar 2026 | |
| Robert F. Williamson III |
3/4/5
|
Director |
—
mixed-class rows
|
168,846
mixed-class rows
|
$394,522 | +$19,946 | 02 Mar 2026 | |
| Trueblood Wealth Management, LLC |
13F
|
Company |
0.1%
|
119,061
|
$327,418 | — | 31 Dec 2025 | |
| Taylor & Morgan Wealth Management, LLC |
13F
|
Company |
0.08%
|
97,000
|
$266,750 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.08%
|
95,800
|
$263,450 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.08%
|
95,193
|
$261,781 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.08%
|
92,791
|
$255,175 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.08%
|
91,557
|
$251,782 | — | 31 Dec 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.08%
|
86,212
|
$237,000 | — | 31 Dec 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.07%
|
83,470
|
$229,543 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.07%
|
82,476
|
$226,809 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.07%
|
81,441
|
$223,963 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.07%
|
81,296
|
$223,564 | — | 31 Dec 2025 | |
| Graham Capital Management, L.P. |
13F
|
Company |
0.07%
|
80,193
|
$220,531 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Perspective Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Maria E. Martinez | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Frank Morich | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Robert F. Williamson III | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Heidi Henson | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Lori A. Woods | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Johan M. Spoor | CATX | Stock option (right to buy) | Award | 735,000 | 735,000 | 02 Mar 2026 | Direct | |||
| Jonathan Robert Hunt | CATX | Stock option (right to buy) | Award | 90,000 | 90,000 | 02 Mar 2026 | Direct | |||
| Markus Puhlmann | CATX | Stock option (right to buy) | Award | 150,000 | 150,000 | 02 Mar 2026 | Direct | |||
| Jonathan Robert Hunt | CATX | Common Stock | Purchase | 22.5% | $22,295 | $2.03 | 11,000 | 59,800 | 13 Nov 2025 | Direct |
| Robert F. Williamson III | CATX | Common Stock | Purchase | 2595.1% | $19,946 | $2.10 | 9,498 | 9,864 | 12 Nov 2025 | RFW3 Revocable Trust |
| Joel Sendek | CATX | Stock option (right to buy) | Award | 600,000 | 600,000 | 04 Sep 2025 | Direct | |||
| Maria E. Martinez | CATX | Stock option (right to buy) | Award | 75,000 | 75,000 | 03 Sep 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.